Quantcast
Last updated on April 21, 2014 at 9:22 EDT

Latest ViaCyte Inc. Stories

2014-02-06 08:29:38

-- Potentially transformative therapy for individuals with type 1 diabetes nearing major milestone -- NEW YORK and SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, and ViaCyte, Inc., a leading regenerative medicine company, jointly announced that JDRF is providing additional milestone-based funding for the continued development of ViaCyte's VC-01(TM) encapsulated cell therapy product candidate for the treatment...

2013-12-19 08:28:04

SAN DIEGO, Dec. 19, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a) Mr. Foletta is a seasoned financial executive with over 30 years of corporate experience. He was most recently senior vice president and Chief Financial Officer at Amylin...

2013-12-02 12:26:27

SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today announced it will present at the 2013 Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013 at 1:30 PM EST / 10:30 PM PST at the New York Palace Hotel. (Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a) During the presentation, Paul Laikind, ViaCyte's President and Chief Executive...

2013-10-29 08:33:56

SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty foreign. These patents enhance the Company's already strong proprietary position for its VC-01(TM) combination product as well as other applications of its...

2013-10-16 12:24:47

SAN DIEGO, Oct. 16, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today announced that it will present a scientific overview at the JDRF 8(th) Annual T1D Global Path to a Cure Symposium on Saturday, October 19, 2013, at 2:10 PM PT in Redmond, Washington. The presentation will be given by Eugene Brandon, Ph.D., Director of Strategic Relations & Project Management at ViaCyte....

2013-10-10 16:26:56

SAN DIEGO, Oct. 10, 2013 /PRNewswire/ -- ViaCyte, Inc. announced today that an update on the Company's progress toward a transformative stem cell-derived cell therapy for the treatment of type 1 diabetes will be presented at the 3(rd) Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14-16 in La Jolla, California. The presentation will be given by Eugene Brandon, Ph.D., Director of Strategic Relations & Project Management at...

2013-07-10 08:26:25

Provides match for $10.1M CIRM Strategic Partnership Award SAN DIEGO, July 10, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock. The...

2013-02-13 08:28:49

-- Treatment being developed would use encapsulation to protect new insulin-producing cells derived from a stem cell precursor -- NEW YORK and SAN FRANCISCO, Feb. 13, 2013 /PRNewswire-USNewswire/ -- JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, and the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, announced that they are providing additional funding for the development of a novel stem cell therapy by San...

2013-01-31 08:30:47

SAN DIEGO, Jan. 31, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted 20 patents worldwide in 2012, eight U.S. and twelve foreign. These patents bolster the Company's already strong proprietary position for its ground-breaking diabetes product, VC-01, as well as other applications of its broad...

2012-10-29 07:26:31

SAN DIEGO, Oct. 29, 2012 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Steve R. Altman has been appointed to its Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20121029/LA00395LOGO) Mr. Altman began his career with the San Diego law firm of Gray, Cary, Ames & Frye (now DLA Piper), where he specialized in intellectual property, mergers and acquisitions,...